Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis.

BACKGROUND AND PURPOSE Spectroscopic examination of multiple sclerosis (MS) patients has revealed abnormally low N-acetyl-aspartate (NAA) signal intensity, even in brain tissue that appears normal on high-resolution structural MR images but has yielded inconclusive evidence to distinguish the well-documented clinical differences between MS subtypes. This study used proton MR spectroscopic imaging (MRSI) and high-resolution MR imaging to characterize metabolite profiles in normal-appearing brain tissue of relapsing-remitting multiple sclerosis (RRMS) and secondary progressive (SP) MS. METHODS Volumetric spiral MRSI was used together with high-resolution MR imaging to derive absolute measures of metabolite concentrations separately in normal-appearing supratentorial cerebral gray matter and white matter in five RRMS patients, five SPMS patients, and nine age-matched controls. Structural MR images were segmented into compartments of gray matter, white matter, CSF, and lesions, and metabolite signals per unit of tissue volume were calculated for gray matter and white matter separately. RESULTS Only the SPMS group had significantly lower NAA concentrations in normal-appearing gray matter compared with concentrations in controls. NAA in normal-appearing white matter was equally reduced in RRMS and SPMS patients. The functional relevance of this brain metabolite measure was suggested by the observed but statistically nonsignificant correlation between higher disability scores on the Expanded Disability Status Scale and lower gray matter NAA concentrations. CONCLUSION The otherwise occult abnormality in supratentorial gray matter in SPMS but not RRMS may explain the more severe physical and cognitive impairments afflicting patients with SPMS that do not correlate well with visible lesion burden.

[1]  K. Lim,et al.  Segmentation of MR Brain Images into Cerebrospinal Fluid Spaces, White and Gray Matter , 1989, Journal of computer assisted tomography.

[2]  R I Grossman,et al.  Total brain N-acetylaspartate , 2000, Neurology.

[3]  W R Kinkel,et al.  High‐Resolution Fluorodeoxyglucose Positron Emission Tomography Shows Both Global and Regional Cerebral Hypometabolism in Multiple Sclerosis , 1998, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[4]  P. Matthews,et al.  Thalamic neurodegeneration in multiple sclerosis , 2002, Annals of neurology.

[5]  J Star-Lack,et al.  Reduced spatial side lobes in chemical‐shift imaging , 1999, Magnetic resonance in medicine.

[6]  N. Otsu A threshold selection method from gray level histograms , 1979 .

[7]  M S Buchsbaum,et al.  Whole-brain diffusion MR histograms differ between MS subtypes , 2000, Neurology.

[8]  P M Matthews,et al.  Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. , 1998, Brain : a journal of neurology.

[9]  K O Lim,et al.  In vivo spectroscopic quantification of the N‐acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: Effects of normal aging , 1999, Magnetic resonance in medicine.

[10]  E. Sullivan,et al.  Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease , 2000, The Lancet.

[11]  G. Barker,et al.  1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis , 1997, Journal of neurology, neurosurgery, and psychiatry.

[12]  P Kapeller,et al.  Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. , 2002, Brain : a journal of neurology.

[13]  F. Mcdowell,et al.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS , 1965, Annals of the New York Academy of Sciences.

[14]  G. Glover,et al.  Regularized higher‐order in vivo shimming , 2002, Magnetic resonance in medicine.

[15]  G. Fein,et al.  Biochemical alterations in multiple sclerosis lesions and normal‐appearing white matter detected by in vivo 31P and 1H spectroscopic imaging , 1994, Annals of neurology.

[16]  P. Dupont,et al.  Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis , 1997, Multiple sclerosis.

[17]  Kishore Bhakoo,et al.  Spectral profiles of cultured neuronal and glial cells derived from HRMAS 1H NMR spectroscopy , 2002, NMR in biomedicine.

[18]  H. Tallan Studies on the distribution of N-acetyl-L-aspartic acid in brain. , 1957, The Journal of biological chemistry.

[19]  M Rovaris,et al.  Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. , 2003, Brain : a journal of neurology.

[20]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[21]  M W Weiner,et al.  1H MRSI of normal appearing white matter in multiple sclerosis , 1997, Multiple sclerosis.

[22]  R. Lenkinski,et al.  MR spectroscopy in the evaluation of enhancing lesions in the brain in multiple sclerosis. , 1996, AJNR. American journal of neuroradiology.

[23]  K O Lim,et al.  In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease. , 1999, Archives of general psychiatry.

[24]  J. Babb,et al.  Relapsing-remitting multiple sclerosis and whole-brain N-acetylaspartate measurement: evidence for different clinical cohorts initial observations. , 2002, Radiology.

[25]  Hristian,et al.  RELAPSES AND PROGRESSION OF DISABILITY IN MULTIPLE SCLEROSIS , 2000 .

[26]  O. Petroff,et al.  Symbiosis between in vivo and in vitro NMR spectroscopy: the creatine, N-acetylaspartate, glutamate, and GABA content of the epileptic human brain. , 1995, Magnetic resonance imaging.

[27]  W. Mcdonald Relapse, remission, and progression in multiple sclerosis. , 2000, The New England journal of medicine.

[28]  C. Svarer,et al.  Rate Dependence of Regional Cerebral Activation during Performance of a Repetitive Motor Task: A PET Study , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[29]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[30]  R. Tarducci,et al.  Localized (1)H magnetic resonance spectroscopy in mainly cortical gray matter of patients with multiple sclerosis. , 2002, Journal of neurology.

[31]  David H. Miller,et al.  Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis , 2002, Annals of neurology.

[32]  J. Frahm,et al.  Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. , 1999, AJNR. American journal of neuroradiology.

[33]  Jullie W Pan,et al.  Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T , 1996, Magnetic resonance in medicine.

[34]  P. Matthews,et al.  Imaging of axonal damage in multiple sclerosis: Spatial distribution of magnetic resonance imaging lesions , 1997, Annals of neurology.